Today Fiona Mischel talks with Mark Kotter, Founder and CEO of bit.bio, about the impact of synthetic biology on the future of medicine. Technologies like human cell reprogramming are taking us beyond the “Brothers Wright Flight'' of early CAR-T therapies, which, while effective, are expensive, cumbersome, and difficult to target. Mark Kotter is dedicated to bringing cell therapies to all patients. Tune in to hear how this vision can be achieved, what challenges we face next, and the breadth of opportunities synbio is creating. You can learn more about human cell reprogramming at www.bit.bio

Check out this week’s sponsor: Form Bio 

Mark Kotter is a stem cell biologist and neurosurgeon at the University of Cambridge. Aged nineteen, he pursued a medical career to serve others and make a difference in people’s lives. He became fascinated by synthetic biology. He is the founder of bit.bio and co-founder of the cultured meat start-up Meatable.

Connect with Mark: @MarkKotter

Connect with Fiona: @FionaRMischel

Stay updated on the latest news in synthetic biology, check out our weekly newsletter, and follow us on social media:

Twitter | LinkedIn | Facebook

Learn more about SynBioBeta events! Click here for more information.